Albert Driver
Pulmonary Disease · Sellersville, PANPI 1811973803
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,963 of the $105,606 with a category attached, or 74.8%. 27 manufacturers reported payments, led by GSK at 47.9% of the total. Reporting peaked in 2019 at $52,200 and has fallen 99.8% since, to $125 in 2023. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $264.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$51K
- Regeneron Healthcare Solutions, Inc.$33K
- Sanofi$13K
- Genentech USA, Inc.$5K
- AstraZeneca$2K
- Boehringer Ingelheim$635
- plus $2K from 21 others
What the payments were for
- Consulting fees$13,04512%
- Speaking & faculty fees$78,96375%
- Travel & lodging$4,9605%
- Food & beverage$8,6128%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 105 | $50,585 |
| Regeneron Healthcare Solutions, Inc. | 59 | $33,409 |
| Sanofi | 21 | $12,619 |
| Genentech USA, Inc. | 20 | $4,828 |
| AstraZeneca(2 entities) | 61 | $1,612 |
| Boehringer Ingelheim | 28 | $635 |
| Sunovion Pharmaceuticals Inc. | 27 | $380 |
| Insmed, Inc. | 14 | $370 |
| Mylan Specialty L.p. | 14 | $237 |
| Grifols USA, LLC | 6 | $118 |
| Circassia Inc. | 5 | $93 |
| Novartis | 6 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Philips North America LLC | 5 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $66 |
| Shire North American Group Inc | 4 | $64 |
| Harmony Biosciences LLC | 2 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Eisai Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Vapotherm Inc | 2 | $33 |
| Advanced Respiratory, Inc | 1 | $28 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Gilead | 1 | $21 |
| United Therapeutics Corporation | 1 | $21 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,606 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Sellersville
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.